Some Reference Material - NECP/SCCP - Advanced Prostate...

Advanced Prostate Cancer

21,046 members26,252 posts

Some Reference Material - NECP/SCCP

skiingfiend profile image
2 Replies

-----

I am constantly updating this post as I come across additional relevant material.

-----

Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons, 2024

ascopubs.org/doi/10.1200/ED....

Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer, 2023

ncbi.nlm.nih.gov/pmc/articl...

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives, 2023

ncbi.nlm.nih.gov/pmc/articl...

Neuroendocrine Tumor Lu-177-Dotatate Therapy, 2023

ncbi.nlm.nih.gov/books/NBK5...

Neuroendocrine and Aggressive-Variant Prostate Cancer, 2020

ncbi.nlm.nih.gov/pmc/articl...

Special Note:

BXCL701 Gains Fast Track Designation for mCRPC Treatment!

targetedonc.com/view/bxcl70...

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

clinicaltrials.ucbraid.org/...

AOH1996 for the Treatment of Refractory Solid Tumors

cityofhope.org/targeted-che...

clinicaltrials.gov/study/NC...

------

The diagram is from - Current and emerging therapies for neuroendocrine prostate cancer, 2022. I got this paper using the Elsevier patient access program.

Written by
skiingfiend profile image
skiingfiend
To view profiles and participate in discussions please or .
Read more about...
2 Replies
j-o-h-n profile image
j-o-h-n

You sure it's not a photo from the Odysseus' moon landing. (Tip me over in the clover....)

BTW I checked my black book and you're still in the plus section.....

Good Luck, Good Health and Good Humor.

j-o-h-n

skiingfiend profile image
skiingfiend in reply to j-o-h-n

Just barely hanging on I bet, we'll see how I fare after my next couple of posts.

Cheers

You may also like...

Highly effective targeted therapy for metastatic prostate cancer, using 177Lu-PSMA Radioligand

Europe . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355374/...

Article: PSMA Theranostics Is Poised to Change Prostate Cancer Landscape

success of lutetium Lu 177 dotatate (Lutathera) therapy for neuroendocrine tumor, the field of...

New radiopharmaceutical (Ac-225-PSMA-617) has high rates of remission in early trials

emitter that targets prostate cancer cells. Lu-177-PSMA-617 is a beta particle emitter that targets...

Neuroendocrine vs small cell

with treatment emergent small cell prostate cancer. Is this the same as neuroendocrine prostate...

Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells

next-generation anti-androgen therapy.\\" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716891/